OUR HISTORY

Company Founded by Peter Annad & Peter Leyne.

Dr Munoz-Ferrada hired as a consultant.

First Nuclear medicine radiation detector was developed- Research & Development department established.

Firing weapon control system capabilities for Australian F1-11.

First Nuclear medicine radiation detector was developed- Research & Development department established.

Development of first environmental radiation detectors to be installed in European airports.

Professor acquires all of Globalsonics – Formation of Globalsonics Radiological Services, a division of Globalsonics to service and maintain radiation measurement equipment and calibration.

Globalsonics renamed Institute for medical research.

ReDesign of calibration facility for instrumentation.

Gamma probe research begins.

Globalsonics signed an agreement with Wollongong University for research.

Agreement signed with De La Salle University in the Philippines. – The first clinical trial of Gammaprobe – First design of Envirorad System.

New Austral-Rad detector developed.

Professor developed further technology in Australia for the worldwide market. Many relationships made with universities research centres and manufacturers throughout the world.

history made at NSW Parliament House, free trade agreement signed and a joint venture created between Globalsonics & Landauer Inc, USA. The first bilateral free trading agreement between the USA and Australia in the area of Biotechnology.

Globalsonics designs the Fukushima 3, a handheld contamination detector utilised by Police Services in the aftermath of the Fukushima Nuclear Power Plant accident. Today the unit has applications in the industrial sector.

Globalsonics released the new generation “Wireless Gammaprobe Surgical Explorer”. Adding knowledge and expertise in surgery, nuclear medicine, physics and engineering.

Abdulla Fouad is appointed as representatives for Globalsonics in Saudi Arabia to distribute our EnviroRad System. Today there are 8 systems operating in Hospitals located around Saudi.

expected announcement of latest R&D project, clinical trials on-going…